TSH receptor hyperstimulation in the orbit leads to glycosaminoglycan secretion by pre-adipocyte fibroblasts and an increase in the volume of intraorbital tissues.
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Thyroid Eye Disease (TED) Thyroid Eye Disease (TED) Pathophysiology Pathophysiology
TED is an orbital inflammatory disease involving T lymphocytes, B lymphocytes and fibroblasts.
TED results from immunological cross-reactivity between thyroid and orbital tissue antigens (TSH receptor).
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TSH receptor hyperstimulation in the orbit leads to glycosaminoglycan secretion by pre-adipocyte fibroblasts and an increase in the volume of intraorbital tissues.
Eye muscles, connective tissue and fat are infiltrated by lymphocytes and are the target of acute inflammation.
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Given this pathophysiology, anti-inflammatory interventions are utilized.
Of these, biologics will become the preferred and increasingly targeted therapy. 
Ophthalmic Technology Assessment Ophthalmic Technology Assessment Conclusion Conclusion
Orbital radiation has a limited role in treating non-sight threatening TED. The effect may be limited to improving or halting progression of ocular dysmotility (vertical). Unclear as to whether improved motility translates into enhanced functioning and quality of life.
Radiation Risks
Risk of definite radiation retinopathy within 10 years-1-2% Risk of possible radiation retinopathy within 10 years-21% Contraindicated-severe htn, diabetes Mutagenic and carcinogenic potential in those <35 years old Risk of radiation induced cataract
Orbital Radiation Orbital Radiation Recommendations Recommendations --Limited Limited
Patients with active disease with diplopia or ocular restriction not responsive to steroid therapy alone.
Rituximab (RTX) Rituximab (RTX)
Mouse -human chimeric monoclonal antibody targeting CD20 protein on pre-B and mature B lymphocytes.
Blocks B-cell activation and differentiation.
Does not affect B cell regeneration from stem cells nor immunoglobulin production from B cells.
Rituximab Rationale Rituximab Rationale
RTX blunts the active inflammatory phase, inducing a 4-6+ month B cell depletion with no change in serum immunoglobulins.
RTX-induced depletion orbital B cells may interfere with antigen presentation and T cells. 
Rituximab Effects Rituximab Effects

Biologics -Rituximab
Highly selective, targeted biologic. Reduces overall inflammation (CAS) rather than just improve vertical diplopia. Potentially more effective than radiation. Lower potential complication rate than radiation. Fewer side effects than steroids. Cost comparable to radiation.
The Present The Present
No single intervention including biologics provides a cure. All current therapies remain "palliative" and currently target only a section of a complex immunologic cascade.
Biologics currently are the best technology available with the potential to deliver targeted therapy with the fewest side effects.
